114 related articles for article (PubMed ID: 35561284)
1. Association of Chronic Hepatitis B Infection and Antiviral Treatment With the Development of the Extrahepatic Malignancies: A Nationwide Cohort Study.
Lee DH; Chung SW; Lee JH; Kim HY; Chung GE; Kim MS; Yang BR; Nam JY; Lee YB; Kim YJ; Yoon JH
J Clin Oncol; 2022 Oct; 40(29):3394-3405. PubMed ID: 35561284
[TBL] [Abstract][Full Text] [Related]
2. Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000-Korean outcome study.
Lim J; Lee JB; An J; Song GW; Kim KM; Lee HC; Shim JH
J Viral Hepat; 2022 Sep; 29(9):756-764. PubMed ID: 35718999
[TBL] [Abstract][Full Text] [Related]
3. Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients.
Cho YY; Lee JH; Chang Y; Nam JY; Cho H; Lee DH; Cho EJ; Lee DH; Yu SJ; Lee JM; Kim YJ; Yoon JH
J Viral Hepat; 2018 Oct; 25(10):1161-1171. PubMed ID: 29741286
[TBL] [Abstract][Full Text] [Related]
4. Long-term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk - a cohort study of 44 494 subjects.
Wong GL; Tse YK; Yip TC; Chan HL; Tsoi KK; Wong VW
Aliment Pharmacol Ther; 2017 May; 45(9):1213-1224. PubMed ID: 28239880
[TBL] [Abstract][Full Text] [Related]
5. Impact of nucleos(t)ide analog treatment on the development of malignancy in patients with chronic hepatitis B.
Kim SS; Ahn EK; Cho SY; Park RW; Cho HJ; Kim JH; Kim HG; Lee GR; Hwang SH; Yang MJ; Cheong JY; Cho SW
Medicine (Baltimore); 2018 Jun; 97(24):e11087. PubMed ID: 29901622
[TBL] [Abstract][Full Text] [Related]
6. Extrahepatic malignancies in metabolic dysfunction-associated fatty liver disease: A nationwide cohort study.
Park MK; Hur MH; Moon HS; Shin H; Chung SW; Won S; Lee YB; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
Liver Int; 2024 Mar; 44(3):799-810. PubMed ID: 38230848
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.
Jung SK; Kim KA; Ha SY; Lee HK; Kim YD; Lee BH; Paik WH; Kim JW; Bae WK; Kim NH; Lee JS; Jwa YJ
Clin Mol Hepatol; 2015 Mar; 21(1):41-8. PubMed ID: 25834801
[TBL] [Abstract][Full Text] [Related]
8. Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma.
Wong GL; Tse YK; Chan HL; Yip TC; Tsoi KK; Wong VW
Aliment Pharmacol Ther; 2016 Apr; 43(7):802-13. PubMed ID: 26843444
[TBL] [Abstract][Full Text] [Related]
9. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
Wang X; Liu X; Dang Z; Yu L; Jiang Y; Wang X; Yan Z
Gut Liver; 2020 Mar; 14(2):232-247. PubMed ID: 31158948
[TBL] [Abstract][Full Text] [Related]
10. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk.
Ren P; Cao Z; Mo R; Liu Y; Chen L; Li Z; Zhou T; Lu J; Liu Y; Guo Q; Chen R; Zhou H; Xiang X; Cai W; Wang H; Bao S; Xu Y; Gui H; Xie Q
Expert Opin Biol Ther; 2018 Oct; 18(10):1085-1094. PubMed ID: 30182763
[TBL] [Abstract][Full Text] [Related]
11. Long-term prognosis of patients with hepatitis B infection: causes of death and utility of nucleos(t)ide analogue therapy.
Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabtake S; Ito T
J Gastroenterol; 2015 Jul; 50(7):795-804. PubMed ID: 25376770
[TBL] [Abstract][Full Text] [Related]
12. Add-on pegylated interferon augments hepatitis B surface antigen clearance
Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
[TBL] [Abstract][Full Text] [Related]
13. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.
Cho JY; Paik YH; Sohn W; Cho HC; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Gut; 2014 Dec; 63(12):1943-50. PubMed ID: 24615378
[TBL] [Abstract][Full Text] [Related]
14. Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy.
Chien NH; Huang YT; Wu CY; Chang CY; Wu MS; Kao JH; Mo LR; Tai CM; Lin CW; Yang TH; Lin JT; Hsu YC
BMC Gastroenterol; 2017 Dec; 17(1):154. PubMed ID: 29221441
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
[TBL] [Abstract][Full Text] [Related]
16. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
Kim GA; Lim YS; Han S; Choi J; Shim JH; Kim KM; Lee HC; Lee YS
Gut; 2018 May; 67(5):945-952. PubMed ID: 29055908
[TBL] [Abstract][Full Text] [Related]
17. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation.
Choi GH; Kim GA; Choi J; Han S; Lim YS
Aliment Pharmacol Ther; 2019 Jul; 50(2):215-226. PubMed ID: 31135074
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients.
Chung GE; Cho EJ; Lee JH; Yoo JJ; Lee M; Cho Y; Lee DH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Zoulim F
Clin Mol Hepatol; 2017 Mar; 23(1):66-73. PubMed ID: 28190329
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients.
Jung KS; Park JY; Chon YE; Kim HS; Kang W; Kim BK; Kim SU; Kim do Y; Han KH; Ahn SH
J Gastroenterol; 2016 Aug; 51(8):830-9. PubMed ID: 26687058
[TBL] [Abstract][Full Text] [Related]
20. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
